Premium
POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R‐CHP VERSUS R‐CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL
Author(s) -
Tilly H.,
Flowers C.,
Friedberg J.W.,
Herbaux C.,
Morschhauser F.,
Sehn L.H.,
Sharman J.,
Trněný M.,
Lee C.,
Salles G.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.36_2629
Subject(s) - medicine , vincristine , rituximab , diffuse large b cell lymphoma , chop , placebo , phases of clinical research , oncology , regimen , cyclophosphamide , surgery , gastroenterology , lymphoma , chemotherapy , pathology , alternative medicine
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom